KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
Holding KALV?
Track your performance easily

KalVista Pharmaceuticals (KALV) Ownership - Who Owns KalVista Pharmaceuticals?

380 Followers

KalVista Pharmaceuticals (KALV) Ownership Overview

11.35%15.02%3.70%9.41%60.53%
11.35% Insiders
3.70% Other Institutional Investors
9.41% ETFs
60.53% Public Companies and
Individual Investors
The ownership structure of KalVista Pharmaceuticals (KALV) stock is a mix of institutional, retail, and individual investors. Approximately 28.12% of the company’s stock is owned by Institutional Investors, 11.35% is owned by Insiders, and 60.53% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Feb 16, 2024
xxxxxxxxxxxxx
$612825
Feb 16, 2024
xxxxxxxxxxxxx
$598290
Feb 16, 2024
xxxxxxxxxxxxx
$422565
Feb 16, 2024
xxxxxxxxxxxxx
$875340

Recent Hedge Fund Trading Activity

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
4,824,731Insider9.90%54,278,224
3,227,620Institution6.63%36,310,725
2,022,076Institution4.15%22,748,355
1,723,050Institution3.54%19,384,313
1,642,102Institution3.37%18,473,648
535,717Institution1.10%6,026,816
530,716Institution1.09%5,970,555
500,000Institution1.03%5,625,000
434,248Institution0.89%4,885,290
341,503Institution0.70%3,841,909

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
3,227,620Institution6.63%36,310,725
1,642,102Institution3.37%18,473,648
434,248Institution0.89%4,885,290
341,503Institution0.70%3,841,909
310,823Institution0.64%3,496,759
278,261Institution0.57%3,130,436
194,062Institution0.40%2,183,198
189,231Institution0.39%2,128,849
127,300Institution0.26%1,432,125
110,720Institution0.23%1,245,600

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,199,834Institution2.46%13,894,078
974,454Institution2.00%11,332,900
565,016Institution1.16%6,542,885
471,242Institution0.97%4,999,878
348,274Institution0.71%4,050,427
210,000Institution0.43%2,442,300
176,751Institution0.36%2,046,777
88,239Institution0.18%1,026,220
75,478Institution0.15%800,822
60,797Institution0.12%624,385

FAQ

Who Owns KalVista Pharmaceuticals (KALV)?
According to the latest TipRanks data, approximately 3.70% of the company's stock is held by institutional investors, 11.35% is held by insiders, and 60.53% is held by retail investors.
    What percentage of KalVista Pharmaceuticals (KALV) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 3.70% of KalVista Pharmaceuticals (KALV) stock is held by institutional investors.
      What percentage of KalVista Pharmaceuticals (KALV) stock is held by retail investors?
      According to the latest TipRanks data, approximately 60.53% of KalVista Pharmaceuticals (KALV) stock is held by retail investors.
        Who owns the most shares of KalVista Pharmaceuticals (KALV)?
        Venrock Healthcare Capital Partners III, L.P. owns the most shares of KalVista Pharmaceuticals (KALV).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis